O	0	20	Hypocholesterolaemic	Hypocholesterolaemic	JJ	B-NP
O	21	24	and	and	CC	I-NP
O	25	36	antioxidant	antioxidant	JJ	I-NP
O	37	44	effects	effect	NNS	I-NP
O	45	47	of	of	IN	B-PP
O	48	59	Glycyrrhiza	Glycyrrhiza	NN	B-NP
O	60	66	glabra	glabra	NN	I-NP
O	67	68	(	(	(	O
O	68	72	Linn	Linn	NN	B-NP
O	72	73	)	)	)	O
O	74	76	in	in	IN	B-PP
O	77	81	rats	rat	NNS	B-NP
O	81	82	.	.	.	O

O	83	86	The	The	DT	B-NP
O	87	107	hypocholesterolaemic	hypocholesterolaemic	JJ	I-NP
O	108	111	and	and	CC	I-NP
O	112	123	antioxidant	antioxidant	JJ	I-NP
O	124	131	effects	effect	NNS	I-NP
O	132	134	of	of	IN	B-PP
O	135	146	Glycyrrhiza	Glycyrrhiza	NN	B-NP
O	147	153	glabra	glabra	NN	I-NP
O	154	155	(	(	(	O
O	155	157	GG	GG	NN	B-NP
O	157	158	)	)	)	O
B-Organ	159	163	root	root	NN	B-NP
O	164	170	powder	powder	NN	I-NP
O	171	175	were	be	VBD	B-VP
O	176	184	examined	examine	VBN	I-VP
O	185	187	in	in	IN	B-PP
O	188	209	hypercholesterolaemic	hypercholesterolaemic	JJ	B-NP
O	210	214	male	male	JJ	I-NP
O	215	221	albino	albino	NN	I-NP
O	222	226	rats	rat	NNS	I-NP
O	226	227	.	.	.	O

O	228	229	A	A	DT	B-NP
O	230	231	4	4	CD	I-NP
O	231	232	-	-	HYPH	I-NP
O	232	236	week	week	NN	I-NP
O	237	251	administration	administration	NN	I-NP
O	252	254	of	of	IN	B-PP
O	255	257	GG	GG	NN	B-NP
B-Organ	258	262	root	root	NN	I-NP
O	263	269	powder	powder	NN	I-NP
O	270	271	(	(	(	O
O	271	272	5	5	CD	B-NP
O	273	276	and	and	CC	I-NP
O	277	279	10	10	CD	I-NP
O	280	282	gm	gm	NN	I-NP
O	282	283	%	%	NN	I-NP
O	284	286	in	in	IN	B-PP
O	287	291	diet	diet	NN	B-NP
O	291	292	)	)	)	O
O	293	295	to	to	TO	B-PP
O	296	317	hypercholesterolaemic	hypercholesterolaemic	JJ	B-NP
O	318	322	rats	rat	NNS	I-NP
O	323	331	resulted	result	VBD	B-VP
O	332	334	in	in	IN	B-PP
O	335	346	significant	significant	JJ	B-NP
O	347	356	reduction	reduction	NN	I-NP
O	357	359	in	in	IN	B-PP
B-Organism_substance	360	366	plasma	plasma	NN	B-NP
O	366	367	,	,	,	O
B-Organ	368	375	hepatic	hepatic	JJ	B-NP
O	376	381	total	total	JJ	I-NP
O	382	388	lipids	lipid	NNS	I-NP
O	388	389	,	,	,	O
O	390	401	cholesterol	cholesterol	NN	B-NP
O	401	402	,	,	,	O
O	403	416	triglycerides	triglyceride	NNS	B-NP
O	417	420	and	and	CC	O
B-Organism_substance	421	427	plasma	plasma	NN	B-NP
O	428	431	low	low	JJ	I-NP
O	431	432	-	-	HYPH	I-NP
O	432	439	density	density	NN	I-NP
O	440	451	lipoprotein	lipoprotein	NN	I-NP
O	452	455	and	and	CC	I-NP
O	456	460	VLDL	VLDL	NN	I-NP
O	460	461	-	-	HYPH	B-NP
O	461	472	cholesterol	cholesterol	NN	I-NP
O	473	484	accompanied	accompany	VBN	B-VP
O	485	487	by	by	IN	B-PP
O	488	499	significant	significant	JJ	B-NP
O	500	509	increases	increase	NNS	I-NP
O	510	512	in	in	IN	B-PP
O	513	516	HDL	HDL	NN	B-NP
O	516	517	-	-	HYPH	B-NP
O	517	528	cholesterol	cholesterol	NN	I-NP
O	529	535	levels	level	NNS	I-NP
O	535	536	.	.	.	O

O	537	548	Furthermore	Furthermore	RB	B-ADVP
O	548	549	,	,	,	O
O	550	561	significant	significant	JJ	B-NP
O	562	571	increases	increase	NNS	I-NP
O	572	574	in	in	IN	B-PP
B-Organism_substance	575	580	fecal	fecal	JJ	B-NP
O	581	592	cholesterol	cholesterol	NN	I-NP
O	592	593	,	,	,	O
O	594	601	neutral	neutral	JJ	B-NP
O	602	609	sterols	sterol	NNS	I-NP
O	610	613	and	and	CC	O
B-Organism_substance	614	618	bile	bile	NN	B-NP
O	619	623	acid	acid	NN	I-NP
O	624	633	excretion	excretion	NN	I-NP
O	634	639	along	along	IN	B-PP
O	640	644	with	with	IN	B-PP
O	645	647	an	an	DT	B-NP
O	648	656	increase	increase	NN	I-NP
O	657	659	in	in	IN	B-PP
B-Organ	660	667	hepatic	hepatic	JJ	B-NP
O	668	671	HMG	HMG	NN	I-NP
O	671	672	-	-	HYPH	B-NP
O	672	675	CoA	CoA	NN	I-NP
O	676	685	reductase	reductase	NN	I-NP
O	686	694	activity	activity	NN	I-NP
O	695	698	and	and	CC	O
B-Organism_substance	699	703	bile	bile	NN	B-NP
O	704	708	acid	acid	NN	I-NP
O	709	719	production	production	NN	I-NP
O	720	724	were	be	VBD	B-VP
O	725	733	observed	observe	VBN	I-VP
O	734	736	in	in	IN	B-PP
O	737	742	these	these	DT	B-NP
O	743	750	animals	animal	NNS	I-NP
O	750	751	.	.	.	O

O	752	755	The	The	DT	B-NP
B-Organ	756	760	root	root	NN	I-NP
O	761	767	powder	powder	NN	I-NP
O	768	782	administration	administration	NN	I-NP
O	783	785	to	to	TO	B-PP
O	786	807	hypercholesterolaemic	hypercholesterolaemic	JJ	B-NP
O	808	812	rats	rat	NNS	I-NP
O	813	817	also	also	RB	B-ADVP
O	818	827	decreased	decrease	VBD	B-VP
B-Organ	828	835	hepatic	hepatic	JJ	B-NP
O	836	841	lipid	lipid	NN	I-NP
O	842	854	peroxidation	peroxidation	NN	I-NP
O	855	859	with	with	IN	B-PP
O	860	861	a	a	DT	B-NP
O	862	873	concomitant	concomitant	JJ	I-NP
O	874	882	increase	increase	NN	I-NP
O	883	885	in	in	IN	B-PP
O	886	896	superoxide	superoxide	NN	B-NP
O	897	906	dismutase	dismutase	NN	I-NP
O	907	908	(	(	(	O
O	908	911	SOD	SOD	NN	B-NP
O	911	912	)	)	)	O
O	913	916	and	and	CC	O
O	917	925	catalase	catalase	NN	B-NP
O	926	936	activities	activity	NNS	I-NP
O	937	940	and	and	CC	O
O	941	946	total	total	JJ	B-NP
O	947	955	ascorbic	ascorbic	JJ	I-NP
O	956	960	acid	acid	NN	I-NP
O	961	968	content	content	NN	I-NP
O	968	969	.	.	.	O

O	970	974	Thus	Thus	RB	B-ADVP
O	974	975	,	,	,	O
O	976	979	the	the	DT	B-NP
O	980	1000	hypocholesterolaemic	hypocholesterolaemic	JJ	I-NP
O	1001	1004	and	and	CC	I-NP
O	1005	1016	antioxidant	antioxidant	JJ	I-NP
O	1017	1024	effects	effect	NNS	I-NP
O	1025	1027	of	of	IN	B-PP
O	1028	1030	GG	GG	NN	B-NP
B-Organ	1031	1035	root	root	NN	I-NP
O	1036	1044	appeared	appear	VBD	B-VP
O	1045	1047	to	to	TO	I-VP
O	1048	1050	be	be	VB	I-VP
O	1051	1059	mediated	mediate	VBN	I-VP
O	1060	1063	via	via	IN	B-PP
O	1064	1065	(	(	(	B-LST
O	1065	1066	i	i	LS	I-LST
O	1066	1067	)	)	)	O
O	1068	1079	accelerated	accelerate	VBD	B-VP
O	1080	1091	cholesterol	cholesterol	NN	B-NP
O	1091	1092	,	,	,	O
O	1093	1100	neutral	neutral	JJ	B-NP
O	1101	1107	sterol	sterol	NN	I-NP
O	1108	1111	and	and	CC	O
B-Organism_substance	1112	1116	bile	bile	NN	B-NP
O	1117	1121	acid	acid	NN	I-NP
O	1122	1133	elimination	elimination	NN	I-NP
O	1134	1141	through	through	IN	B-PP
B-Organism_substance	1142	1147	fecal	fecal	JJ	B-NP
I-Organism_substance	1148	1154	matter	matter	NN	I-NP
O	1155	1159	with	with	IN	B-PP
O	1160	1162	an	an	DT	B-NP
O	1163	1172	increased	increase	VBN	I-NP
B-Organ	1173	1180	hepatic	hepatic	JJ	I-NP
B-Organism_substance	1181	1185	bile	bile	NN	I-NP
O	1186	1190	acid	acid	NN	I-NP
O	1191	1201	production	production	NN	I-NP
O	1202	1205	and	and	CC	O
O	1206	1207	(	(	(	B-LST
O	1207	1209	ii	ii	LS	I-LST
O	1209	1210	)	)	)	O
O	1211	1220	improving	improve	VBG	B-VP
O	1221	1224	the	the	DT	B-NP
O	1225	1235	activities	activity	NNS	I-NP
O	1236	1238	of	of	IN	B-PP
B-Organ	1239	1246	hepatic	hepatic	JJ	B-NP
O	1247	1250	SOD	SOD	NN	I-NP
O	1250	1251	,	,	,	O
O	1252	1260	catalase	catalase	NN	B-NP
O	1261	1264	and	and	CC	O
O	1265	1275	increasing	increase	VBG	B-VP
O	1276	1279	the	the	DT	B-NP
O	1280	1288	ascorbic	ascorbic	JJ	I-NP
O	1289	1293	acid	acid	NN	I-NP
O	1294	1301	content	content	NN	I-NP
O	1301	1302	.	.	.	O

O	1303	1306	The	The	DT	B-NP
O	1307	1312	normo	normo	AFX	I-NP
O	1312	1313	-	-	HYPH	I-NP
O	1313	1329	cholesterolaemic	cholesterolaemic	JJ	I-NP
O	1330	1337	animals	animal	NNS	I-NP
O	1338	1342	when	when	WRB	B-ADVP
O	1343	1346	fed	feed	VBN	B-VP
O	1347	1351	with	with	IN	B-PP
O	1352	1354	GG	GG	NN	B-NP
B-Organ	1355	1359	root	root	NN	I-NP
O	1360	1366	powder	powder	NN	I-NP
O	1367	1369	at	at	IN	B-PP
O	1370	1372	10	10	CD	B-NP
O	1373	1375	gm	gm	NN	I-NP
O	1375	1376	%	%	NN	I-NP
O	1377	1382	level	level	NN	I-NP
O	1382	1383	,	,	,	O
O	1384	1394	registered	register	VBD	B-VP
O	1395	1396	a	a	DT	B-NP
O	1397	1408	significant	significant	JJ	I-NP
O	1409	1416	decline	decline	NN	I-NP
O	1417	1419	in	in	IN	B-PP
B-Organism_substance	1420	1426	plasma	plasma	NN	B-NP
O	1427	1432	lipid	lipid	NN	I-NP
O	1433	1441	profiles	profile	NNS	I-NP
O	1442	1445	and	and	CC	O
O	1446	1448	an	an	DT	B-NP
O	1449	1457	increase	increase	NN	I-NP
O	1458	1460	in	in	IN	B-PP
O	1461	1464	HDL	HDL	NN	B-NP
O	1464	1465	-	-	HYPH	B-NP
O	1465	1476	cholesterol	cholesterol	NN	I-NP
O	1477	1484	content	content	NN	I-NP
O	1484	1485	.	.	.	O

O	1486	1489	The	The	DT	B-NP
O	1490	1501	antioxidant	antioxidant	JJ	I-NP
O	1502	1508	status	status	NN	I-NP
O	1509	1511	of	of	IN	B-PP
O	1512	1517	these	these	DT	B-NP
O	1518	1525	animals	animal	NNS	I-NP
O	1526	1530	also	also	RB	B-ADVP
O	1531	1534	was	be	VBD	B-VP
O	1535	1543	improved	improve	VBN	I-VP
O	1544	1548	upon	upon	IN	B-PP
O	1549	1558	treatment	treatment	NN	B-NP
O	1558	1559	.	.	.	O

